How is Blincyto taken / administered?
Medically reviewed by Melisa Puckey, BPharm. Last updated on Feb 24, 2021.
Blincyto (blinatumomab) is a cancer treatment given as a continuous IV infusion over 28 days. You then have a break with no treatment. This is called a treatment cycle which includes the treatment days and treatment-free days.
How many treatment cycles you have will depend on which type of acute lymphoblastic leukemia (ALL) you are treating.
MRD-positive B-cell Precursor ALL:
- One induction cycle (28 days treatment, 14 days no treatment)
- Up to three additional cycles for consolidation (28 days treatment, 14 days no treatment)
Relapsed or Refractory B-cell Precursor ALL:
- Two induction cycles (28 days treatment, 14 days no treatment)
- Three additional cycles for consolidation (28 days treatment, 14 days no treatment)
- Up to four additional cycles of continued therapy (28 days treatment, 56 days no treatment)
Cycles may be interrupted due to adverse reactions.
For more information on dosage and administration of Blincyto click here: Dosage and administration of Blincyto
- Blincyto Professional Information: Accessed 24 February 2021. https://www.drugs.com/pro/blincyto.html
- Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date: Accessed 24 February 2021 : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173178/
Related Medical Questions
- Is Blincyto (blinatumomab) chemotherapy?
- How does Gleevec (imatinib) work?
- What is the lifetime or cumulative dose for Adriamycin?
- Is Sprycel a chemotherapy drug?
- Is there a generic for Gleevec?
- Can I take Gleevec while pregnant?
- What is the cost of Kymriah?
- How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?
- How is Kymriah administered?
- How does Besponsa work to treat acute lymphoblastic leukemia (ALL)?
- What type of drug is Kymriah (tisagenlecleucel)?